Poor
Poorly Aligned
Patient Risk:
Low
Summary
Majority of claims about statin interactions with Pepcid are not supported by the label; only mechanism (12.1) and some pharmacokinetic/interaction details (12.3, 7.1) are indirectly relevant. Several claims about monitoring, timing, and statin-specific guidance are not present in the label, resulting in overall misalignment.
Category Scores
Accurate Statements
Pepcid (famotidine) is an H2 blocker.
12.1
Pepcid reduces stomach acid.
12.1
Most clinically relevant statin interactions depend on metabolism pathways (especially CYP enzymes) and whether gastric pH changes meaningfully affect absorption.
12.3, 7.1
Pepcid can generally be taken without a special timing requirement for most statins.
12.3
Unsupported Statements
In general, H2 blockers do not have the same kind of interaction risk with statins as some other acid-reducing drugs can.
Not supported by label; no label guidance comparing H2 blockers to statin interaction risk.
Proton pump inhibitors (PPIs) can have interaction risk with statins in specific cases.
Not supported by label; no PPI-statin interaction guidance in provided sections.
With typical dosing, Pepcid is not a well-known cause of clinically significant increases or decreases in statin drug levels.
Not supported by label; no statin-specific level-change guidance.
Pepcid is not commonly flagged as a major interaction driver across statins the way certain other drugs are.
Not supported by label; no comparative interaction labeling for statins.
If you are on a statin and using Pepcid regularly or at high doses, it’s reasonable to watch for statin side effects (especially muscle pain/weakness).
Not supported by label; no monitoring guidance tying famotidine to statin myopathy.
Follow the prescriber’s plan for monitoring.
Not supported by label; no label-directed monitoring plan specific to statin-Pepcid use.
Regardless of the exact interaction, the main safety signal people watch for with statins is muscle-related toxicity.
Not supported by label; no statin-specific safety signal emphasized in provided sections.
Seek medical advice promptly if you develop unexplained muscle pain while taking a statin (particularly soon after starting or changing doses of any interacting medication).
Not supported by label; no such patient-directed warning in label excerpts.
Seek medical advice promptly if you develop muscle tenderness while taking a statin (particularly soon after starting or changing doses of any interacting medication).
Not supported by label.
Seek medical advice promptly if you develop muscle weakness while taking a statin (particularly soon after starting or changing doses of any interacting medication).
Not supported by label.
Seek medical advice promptly if you develop dark urine while taking a statin (particularly soon after starting or changing doses of any interacting medication).
Not supported by label.
If your clinician or pharmacist recommended spacing doses for your specific regimen, follow that guidance.
Not supported by label.
Otherwise, taking them at convenient times is usually acceptable.
Not supported by label.
Interaction risk can vary by which statin you take (for example, atorvastatin, simvastatin, rosuvastatin, pravastatin, etc.) and how Pepcid is dosed.
Not supported by label.
Contradictions
Important Omissions
No on-label guidance about interactions between famotidine (Pepcid) and statins; indications and safety warnings do not address statin coadministration.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Mainly pharmacokinetic statements; no explicit new safety risks identified in label sections provided.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Poorly Aligned
Primary Issue
Content includes many non-label statements about statin interactions and monitoring not present in label.
Suggested Improvement
Restrict to on-label information (12.1, 12.3, 7.1); avoid generalized monitoring or timing guidance not in label; clearly separate on-label facts from general pharmacology and statin-specific guidance.